Yeni Nesil Antibiyotikler
Synopsis
The rapid global increase in antimicrobial resistance has created significant challenges in the treatment of infections, particularly those caused by multidrug-resistant bacteria. Pathogens such as extended-spectrum beta-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and multidrug-resistant Pseudomonas aeruginosa have limited the effectiveness of existing antibiotics, increasing the need for novel therapeutic options. Recently developed antibiotics and beta-lactam/beta-lactamase inhibitor combinations offer promising alternatives for treating resistant bacterial infections. Combinations such as ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/cilastatin/relebactam demonstrate activity against Gram-negative bacteria harboring specific resistance mechanisms. Novel antibiotics, including plazomicin, eravacycline, omadacycline, and delafloxacin, offer additional therapeutic options through their distinct mechanisms of action and antibacterial spectra. Cefiderocol represents an important alternative against carbapenem-resistant Gram-negative bacteria owing to its unique siderophore-mediated cellular uptake mechanism. Furthermore, emerging beta-lactamase inhibitors and antibiotic combinations hold considerable potential for future treatment strategies. However, the effectiveness of these agents varies according to bacterial resistance mechanisms, and their clinical safety profiles require careful evaluation. In conclusion, the rational use of novel antibiotics, accurate identification of resistance mechanisms, and appropriate antimicrobial susceptibility testing are essential for improving treatment outcomes and limiting further resistance development. Strengthening antimicrobial stewardship programs and collaboration with clinical microbiology laboratories is crucial for preserving their long-term effectiveness.
References
Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-686.
Wong D, van Duin D. Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs. 2017;77(6):615-628.
Sawa T, Kooguchi K, Moriyama K. Molecular diversity of extended-spectrum β-lactamases and carbapenemases, and antimicrobial resistance. J Intensive Care. 2020;8:13.
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2021;72(7):e169-e183.
Nguyen L, Garcia J, Gruenberg K, MacDougall C. Multidrug-resistant Pseudomonas infections: hard to treat, but hope on the horizon? Curr Infect Dis Rep. 2018;20:23.
Zerbaxa (ceftolozane/tazobactam) [package insert]. Lexington (MA): Cubist Pharmaceuticals; 2014.
Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949-1956.
Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462-1471.
Kalil AC, Zavascki AP. Can ceftolozane–tazobactam treat nosocomial pneumonia? Lancet Infect Dis. 2019;19:1266-1267.
Moya B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:3933-3937.
Gallagher JC, Satlin MJ, Elabor A, Saraiya N, McCreary EK, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis. 2018;5:ofy280.
Sader HS, Flamm RK, Carvalhaes CG, Castanheira M. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018). Diagn Microbiol Infect Dis. 2020;96:114833.
Hernandez-Tejedor A, Merino-Vega CD, Martin-Vivas A, Ruiz de Luna-Gonzalez R, Delgado-Iribarren A, et al. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam. Infection. 2017;45:115-117.
Avycaz (ceftazidime/avibactam) [package insert]. Verona (Italy): GlaxoSmithKline Manufacturing; 2019.
Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62:1380-1389.
Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63:754-762.
Torres A, Rank D, Melnick D, Rekeda L, Chen X, et al. Randomized trial of ceftazidime-avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): analyses per US FDA-specified end points. Open Forum Infect Dis. 2019;6:ofz149.
Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71:2713-2722.
Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, et al. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2016;60:3227-3231.
Grupper M, Sutherland C, Nicolau DP. Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother. 2017;61(10):e01128-17.
Vabomere (meropenem/vaborbactam) [package insert]. Lincolnshire (IL): Melinta Therapeutics, Inc.; 2020.
Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319:788-799.
Tsivkovski R, Lomovskaya O. Biochemical activity of vaborbactam. Antimicrob Agents Chemother. 2020;64(2):e01935-19.
Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319:788-799.
Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7:439-455.
Zemdri (plazomicin) [package insert]. South San Francisco (CA): Achaogen, Inc.; 2018.
Shaeer KM, Zmarlicka MT, Chahine EB, Piccicacco N, Cho JC. Plazomicin: a next-generation aminoglycoside. Pharmacotherapy. 2019;39:77-93.
Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380:729-740.
Xerava (eravacycline) [package insert]. Watertown (MA): Tetraphase Pharmaceuticals, Inc.; 2018.
Zhanel GG, Cheung D, Adam H. Review of eravacycline: a novel fluorocycline antibacterial agent. Drugs. 2016;76:567-588.
Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the IGNITE 1 trial: a randomized clinical trial. JAMA Surg. 2017;152:224-232.
Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin Infect Dis. 2019;69:921-929.
Nuzyra (omadacycline) [package insert]. Boston (MA): Paratek Pharmaceuticals, Inc.; 2018.
Kaushik A, Ammerman NC, Martins O, Parrish NM, Nuermberger EL. In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63:e00470-e519.
Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517-527.
O’Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19:1080-1090.
O’Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med. 2019;380:528-538.
Recarbrio (imipenem/cilastatin/relebactam) [package insert]. Whitehouse Station (NJ): Merck & Co., Inc.; 2019.
Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother. 2014;58:833-838.
Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW, et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study). Clin Infect Dis. 2021;73(11):e4539-e4548.
Motsch J, Murta de Oliveira C, Stus V, Koksal I, Lyulko O, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70:1799-1808.
Fetroja (cefiderocol) [package insert]. Osaka (Japan): Shionogi & Co., Ltd; 2019.
Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, noninferiority trial. Lancet Infect Dis. 2018;18:1319-1328.
Lodise TP, Bassetti M, Ferrer R, Naas T, Niki Y, Paterson DL, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther. 2022;20(5):707-719.
Sader HS, Rhomberg PR, Flamm RK, Jones RN, Castanheira M. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases. J Antimicrob Chemother. 2017;72(6):1696-1703.
Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA. Activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother. 2017;61(9):e00472-17.
Mauri C, Maraolo AE, Di Bella S, Luzzaro F, Principe L. The revival of aztreonam in combination with avibactam against metallo-β-lactamase-producing Gram-negatives: a systematic review of in vitro studies and clinical cases. Antibiotics (Basel). 2021;10(8):1012.
Shapiro AB, Moussa SH, McLeod SM, Durand-Réville T, Miller AA. Durlobactam, a new diazabicyclooctane β-lactamase inhibitor for the treatment of Acinetobacter infections in combination with sulbactam. Front Microbiol. 2021;12:709974.
Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol. 2017;2:17104.
Barnes MD, Kumar V, Bethel CR, Moussa SH, O’Donnell J, Rutter JD, et al. Targeting multidrug-resistant Acinetobacter spp.: sulbactam and the diazabicyclooctenone β-lactamase inhibitor ETX2514 as a novel therapeutic agent. mBio. 2019;10(2):e00159-19.
Bradford PA, Miller AA, O’Donnell J, Mueller JP. Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrhoeae. ACS Infect Dis. 2020;6:1332-1345.
World Health Organization. Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline. 2019.
Cho JC, Crotty MP, Pardo J. Ridinilazole: a novel antimicrobial for Clostridium difficile infection. Ann Gastroenterol. 2019;32(2):134-140.
